You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
A group led by Mount Sinai researchers said this methyltransferase, which is involved in sporulation, could be targeted to fight infections.
The firm's tick-borne pathogens panel was also recently the subject of a clinical study, showing high accuracy in detecting numerous infectious agents.
Based in Warsaw, Poland, the technology was inspired by "ultra-fast" PCR methods from the Wittwer group and Scope plans to launch tests for MRSA and C. diff.
An analysis of more than 900 C. difficile isolates uncovered four phylogenetic lineages, including three lineages in a clade showing recent positive selection on infection-related genes.
The firm aims to stabilize and protect its existing molecular diagnostics business over the next 12 to 18 months, CEO Jack Kenny said.
The four-year loan will be used to develop molecular diagnostic assays for the firm's two test systems, Amplidiag and Novodiag.
Cincinnati, Ohio-based Meridian will acquire Quebec City-based GenePOC for $120 million, and hopes to quickly convert customers to a PCR-based instrument.
The FDA has yet to determine if fecal microbiome transplants should be treated like a drug or like a blood transfusion, the New York Times reports.
Signature Science will assess the validity of metagenomic and metatranscriptomic analyses to detect the transmission of viable pathogens in healthcare settings.
Researchers hope that understanding the etiology of inappropriate testing will help them design a better computerized support tool.
Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.
The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.
In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.
According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.